Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Single-dose oral ciprofloxacin prophylaxis as a
meningococcal meningitis outbreak response:
results of a cluster-randomize...
Study design and primary objective
3-arm cluster-randomized trial to assess the impact of
prophylaxis with single-dose ora...
Interventions
• Arm 1: standard care
• Arm 2: ciprofloxacin to household contacts
– Given by nurse at home <24h of case no...
Statistical analysis
• Cluster-level t-test of log-transformed post-randomization attack
rates
– Inverse variance weights ...
Resistance sub-study methods
• Sample size: 10 villages / 200 individuals in each arm (400 total)
= 20 individuals randoml...
Timeline
20 April: Trial start criteria met in
Madarounfa District, Niger
22 April: First villages included
10 May: First ...
Baseline characteristics of villages
Standard care Household cipro Village-wide cipro
Number of villages 18 17 15
Total po...
Primary results
* Adjusted for log(proportion of village <30y), days between inclusion and reactive vaccination, days from...
Laboratory results
• 52 samples sent from 247 post-randomization cases
– 21 NmC, 31 negative
• Standard care: 16 NmC from ...
Standard care
Household
prophylaxis
Village-wide
prophylaxis
Resistance sub-study - Results
• Baseline carriage of resistant
enterobacteriae was very high
• Trend for increased
preval...
Conclusion
• Village-wide prophylaxis with single-dose oral ciprofloxacin <72h after
meningitis case notification signific...
Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+
Upcoming SlideShare
Loading in …5
×

of

Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+ Slide 1 Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+ Slide 2 Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+ Slide 3 Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+ Slide 4 Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+ Slide 5 Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+ Slide 6 Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+ Slide 7 Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+ Slide 8 Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+ Slide 9 Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+ Slide 10 Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+ Slide 11 Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+ Slide 12 Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+ Slide 13
Upcoming SlideShare
What to Upload to SlideShare
Next
Download to read offline and view in fullscreen.

0 Likes

Share

Download to read offline

Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+

Download to read offline

Single-dose oral ciprofloxacin prophylaxis as a meningococcal meningitis outbreak response: results of a cluster-randomized trial
https://www.meningitis.org/mrf-conference-2017

Related Books

Free with a 30 day trial from Scribd

See all

Related Audiobooks

Free with a 30 day trial from Scribd

See all
  • Be the first to like this

Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+

  1. 1. Single-dose oral ciprofloxacin prophylaxis as a meningococcal meningitis outbreak response: results of a cluster-randomized trial d Madarounfa Health District, Niger Matthew Coldiron, Epicentre 15 November 2017
  2. 2. Study design and primary objective 3-arm cluster-randomized trial to assess the impact of prophylaxis with single-dose oral ciprofloxacin (to household contacts and to entire villages) on the overall meningitis attack rate during an epidemic. Ethics review: CCNE of Niger (003/2016/CCNE) and MSF-ERB (Ref: 1603) Funding: Médecins Sans Frontières Full methods: Coldiron et al. Trials 2017;18:294 Trial registry: clinicaltrials.gov NCT02724046
  3. 3. Interventions • Arm 1: standard care • Arm 2: ciprofloxacin to household contacts – Given by nurse at home <24h of case notification • Arm 3: ciprofloxacin to entire village – Village-wide distribution of ciprofloxacin <72h after declaration of first case from a village • Directly-observed, age-based dosing of ciprofloxacin, including children and pregnant women • Exhaustive censuses in each included village
  4. 4. Statistical analysis • Cluster-level t-test of log-transformed post-randomization attack rates – Inverse variance weights to account for heterogeniety among clusters • Poisson regression adjusting for (prespecified): – age structure of villages – time between randomization and start of epidemic – time between randomization and reactive vaccination – inclusion before/after rains • ICC calculated using ANOVA
  5. 5. Resistance sub-study methods • Sample size: 10 villages / 200 individuals in each arm (400 total) = 20 individuals randomly selected in each of 20 villages, individual written consent • Stool collection at days 0, 7 and 28 • Detection of the carriage of enterobacteriae resistant to cipro and/or cefotaxime by plating on selective media • Simplification of identification / confirmation methods after 5 villages showing very high prevalence of resistant bacteria • Quality control at IAME laboratory, Inserm, Paris, France
  6. 6. Timeline 20 April: Trial start criteria met in Madarounfa District, Niger 22 April: First villages included 10 May: First rains 12 May: First vaccination began 18 May: Last village included (50 villages total in 5 health areas) 23 May: Last case notified
  7. 7. Baseline characteristics of villages Standard care Household cipro Village-wide cipro Number of villages 18 17 15 Total population 26 162 23 621 22 177 Age of cases, mean±SD 18±13 17±15 18±17 Female population (%) 58 55 54 Proportion <30y (%) 78 77 76 Days between inclusion and reactive vaccination, mean±SD 11.1±7.8 10.8±9.5 12.2±8.8 Days between inclusion and first rains, mean±SD 7.2±7.1 6.4±8.1 7.1±6.5
  8. 8. Primary results * Adjusted for log(proportion of village <30y), days between inclusion and reactive vaccination, days from start of epidemic, and whether inclusion of village occurred after the first day of rainfall Standard care Household Cipro Village-wide cipro Post-randomization cases 113 91 43 Attack rate (95%CI), cases/100 000 people 432 (255-738) 386 (219-679) 194 (103-364) Crude attack rate ratio versus standard care (95%CI) Ref 0.89 (0.44-1.82) p=0.75 0.44 (0.18-1.12) p=0.08 Adjusted attack rate ratio versus standard care (95%CI)* Ref 0.88 (0.51-1.51) p=0.64 0.43 (0.22-0.86) p=0.02
  9. 9. Laboratory results • 52 samples sent from 247 post-randomization cases – 21 NmC, 31 negative • Standard care: 16 NmC from 28 tested • Household ppx: 5 NmC from 16 tested • Village-wide ppx: 0 NmC from 8 tested
  10. 10. Standard care Household prophylaxis Village-wide prophylaxis
  11. 11. Resistance sub-study - Results • Baseline carriage of resistant enterobacteriae was very high • Trend for increased prevalence of carriage of Cipro-R enterobacteriae after village-wide distribution – Non-significant difference in change between D7/D0 and D28/D0 between arms (p=0.12) No cipro Village-wide cipro Cipro-R (%) D0 95 95 D7 93 97 D28 95 99 ESBL (%) D0 91 94 D7 87 93 D28 93 93
  12. 12. Conclusion • Village-wide prophylaxis with single-dose oral ciprofloxacin <72h after meningitis case notification significantly reduced attack rates – Could be an attractive new strategy for epidemic response • Faster (can stockpile ciprofloxacin in-country) • Possibly cheaper (low cost of cipro, no cold chain or other materials) • 57% reduction in cases seems much larger than previous model-based estimates for reactive vaccination – Would have preferred more laboratory confirmations, but the confirmed cases follow the same trends • Need more information about potential impact of strategy on antibiotic resistance (both of meningococcus and gut flora)

Single-dose oral ciprofloxacin prophylaxis as a meningococcal meningitis outbreak response: results of a cluster-randomized trial https://www.meningitis.org/mrf-conference-2017

Views

Total views

5,712

On Slideshare

0

From embeds

0

Number of embeds

5,333

Actions

Downloads

3

Shares

0

Comments

0

Likes

0

×